Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway
Background and Aims Nonalcoholic fatty liver disease, especially nonalcoholic steatohepatitis (NASH), has become a major cause of liver transplantation and liver‐associated death. NASH is the hepatic manifestation of metabolic syndrome and is characterized by hepatic steatosis, inflammation, hepatoc...
Gespeichert in:
Veröffentlicht in: | Hepatology (Baltimore, Md.) Md.), 2021-08, Vol.74 (2), p.686-703 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 703 |
---|---|
container_issue | 2 |
container_start_page | 686 |
container_title | Hepatology (Baltimore, Md.) |
container_volume | 74 |
creator | Lan, Tian Yu, Yang Zhang, Jing Li, Haonan Weng, Qiqing Jiang, Shuo Tian, Song Xu, Tonghao Hu, Sha Yang, Guizhi Zhang, Yan Wang, Weixuan Wang, Lexun Zhu, Qing Rong, Xianglu Guo, Jiao |
description | Background and Aims
Nonalcoholic fatty liver disease, especially nonalcoholic steatohepatitis (NASH), has become a major cause of liver transplantation and liver‐associated death. NASH is the hepatic manifestation of metabolic syndrome and is characterized by hepatic steatosis, inflammation, hepatocellular injury, and different degrees of fibrosis. However, there is no US Food and Drug Administration–approved medication to treat this devastating disease. Therapeutic activators of the AMP‐activated protein kinase (AMPK) have been proposed as a potential treatment for metabolic diseases such as NASH. Cordycepin, a natural product isolated from the traditional Chinese medicine Cordyceps militaris, has recently emerged as a promising drug candidate for metabolic diseases.
Approach and Results
We evaluated the effects of cordycepin on lipid storage in hepatocytes, inflammation, and fibrosis development in mice with NASH. Cordycepin attenuated lipid accumulation, inflammation, and lipotoxicity in hepatocytes subjected to metabolic stress. In addition, cordycepin treatment significantly and dose‐dependently decreased the elevated levels of serum aminotransferases in mice with diet‐induced NASH. Furthermore, cordycepin treatment significantly reduced hepatic triglyceride accumulation, inflammatory cell infiltration, and hepatic fibrosis in mice. In vitro and in vivo mechanistic studies revealed that a key mechanism linking the protective effects of cordycepin were AMPK phosphorylation–dependent, as indicated by the finding that treatment with the AMPK inhibitor Compound C abrogated cordycepin‐induced hepatoprotection in hepatocytes and mice with NASH.
Conclusion
Cordycepin exerts significant protective effects against hepatic steatosis, inflammation, liver injury, and fibrosis in mice under metabolic stress through activation of the AMPK signaling pathway. Cordycepin might be an AMPK activator that can be used for the treatment of NASH. |
doi_str_mv | 10.1002/hep.31749 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8457150</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2564444003</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4439-c78a83767d30c6cadacd5c55668ae36093a5297b61efffd078dc850ed2de548d3</originalsourceid><addsrcrecordid>eNp1kc1uEzEURi0EomlhwQsgS2xgMa3HP2PPBimKCkUUiFRYW459J-NqMg6202p2fQSekSfBkFABEt5Y9j0699ofQs9qcloTQs962J6yWvL2AZrVgsqKMUEeohmhklRtzdojdJzSNSGk5VQ9RkelLhvCxAxNixDdZGHrRzzfwOBDNBkS_hhGM9jQh8FbfJXB5FC6mOyzT3g14bnN_qYcw4hDh3MPeP5h-f3u2-EeHF7GkKFY3_vRJMBXfl2Mflzjpcn9rZmeoEedGRI8Pewn6Mub88-Li-ry09t3i_llZTlnbWWlMorJRjpGbGONM9YJK0TTKAOsIS0zgrZy1dTQdZ0jUjmrBAFHHQiuHDtBr_fe7W61AWdhzNEMehv9xsRJB-P135XR93odbrTiQtaCFMHLgyCGrztIWW98sjAMZoSwS5py1VLBBaMFffEPeh12sby7UKLhZRHCCvVqT9kYUorQ3Q9TE_0zUF2-Wv8KtLDP_5z-nvydYAHO9sCtH2D6v0lfnC_3yh95RK3q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2564444003</pqid></control><display><type>article</type><title>Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Lan, Tian ; Yu, Yang ; Zhang, Jing ; Li, Haonan ; Weng, Qiqing ; Jiang, Shuo ; Tian, Song ; Xu, Tonghao ; Hu, Sha ; Yang, Guizhi ; Zhang, Yan ; Wang, Weixuan ; Wang, Lexun ; Zhu, Qing ; Rong, Xianglu ; Guo, Jiao</creator><creatorcontrib>Lan, Tian ; Yu, Yang ; Zhang, Jing ; Li, Haonan ; Weng, Qiqing ; Jiang, Shuo ; Tian, Song ; Xu, Tonghao ; Hu, Sha ; Yang, Guizhi ; Zhang, Yan ; Wang, Weixuan ; Wang, Lexun ; Zhu, Qing ; Rong, Xianglu ; Guo, Jiao</creatorcontrib><description>Background and Aims
Nonalcoholic fatty liver disease, especially nonalcoholic steatohepatitis (NASH), has become a major cause of liver transplantation and liver‐associated death. NASH is the hepatic manifestation of metabolic syndrome and is characterized by hepatic steatosis, inflammation, hepatocellular injury, and different degrees of fibrosis. However, there is no US Food and Drug Administration–approved medication to treat this devastating disease. Therapeutic activators of the AMP‐activated protein kinase (AMPK) have been proposed as a potential treatment for metabolic diseases such as NASH. Cordycepin, a natural product isolated from the traditional Chinese medicine Cordyceps militaris, has recently emerged as a promising drug candidate for metabolic diseases.
Approach and Results
We evaluated the effects of cordycepin on lipid storage in hepatocytes, inflammation, and fibrosis development in mice with NASH. Cordycepin attenuated lipid accumulation, inflammation, and lipotoxicity in hepatocytes subjected to metabolic stress. In addition, cordycepin treatment significantly and dose‐dependently decreased the elevated levels of serum aminotransferases in mice with diet‐induced NASH. Furthermore, cordycepin treatment significantly reduced hepatic triglyceride accumulation, inflammatory cell infiltration, and hepatic fibrosis in mice. In vitro and in vivo mechanistic studies revealed that a key mechanism linking the protective effects of cordycepin were AMPK phosphorylation–dependent, as indicated by the finding that treatment with the AMPK inhibitor Compound C abrogated cordycepin‐induced hepatoprotection in hepatocytes and mice with NASH.
Conclusion
Cordycepin exerts significant protective effects against hepatic steatosis, inflammation, liver injury, and fibrosis in mice under metabolic stress through activation of the AMPK signaling pathway. Cordycepin might be an AMPK activator that can be used for the treatment of NASH.</description><identifier>ISSN: 0270-9139</identifier><identifier>ISSN: 1527-3350</identifier><identifier>EISSN: 1527-3350</identifier><identifier>DOI: 10.1002/hep.31749</identifier><identifier>PMID: 33576035</identifier><language>eng</language><publisher>United States: Wolters Kluwer Health, Inc</publisher><subject>AMP-Activated Protein Kinases - metabolism ; Animals ; Cell Line ; Cordycepin ; Deoxyadenosines - pharmacology ; Deoxyadenosines - therapeutic use ; Fatty liver ; Fibrosis ; Hepatocytes ; Hepatology ; Humans ; Inflammation ; Kinases ; Liver ; Liver - drug effects ; Liver - immunology ; Liver - pathology ; Liver Cirrhosis - immunology ; Liver Cirrhosis - pathology ; Liver Cirrhosis - prevention & control ; Liver diseases ; Liver transplantation ; Metabolic disorders ; Metabolic rate ; Metabolic syndrome ; Mice ; Natural products ; Non-alcoholic Fatty Liver Disease - drug therapy ; Non-alcoholic Fatty Liver Disease - immunology ; Non-alcoholic Fatty Liver Disease - pathology ; Original ; Phosphorylation ; Protein kinase ; Signal transduction ; Signal Transduction - drug effects ; Signal Transduction - immunology ; Steatosis ; Traditional Chinese medicine</subject><ispartof>Hepatology (Baltimore, Md.), 2021-08, Vol.74 (2), p.686-703</ispartof><rights>2021 The Authors. published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.</rights><rights>2021 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.</rights><rights>2021. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4439-c78a83767d30c6cadacd5c55668ae36093a5297b61efffd078dc850ed2de548d3</citedby><cites>FETCH-LOGICAL-c4439-c78a83767d30c6cadacd5c55668ae36093a5297b61efffd078dc850ed2de548d3</cites><orcidid>0000-0002-5783-6883</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhep.31749$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhep.31749$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,777,781,882,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33576035$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lan, Tian</creatorcontrib><creatorcontrib>Yu, Yang</creatorcontrib><creatorcontrib>Zhang, Jing</creatorcontrib><creatorcontrib>Li, Haonan</creatorcontrib><creatorcontrib>Weng, Qiqing</creatorcontrib><creatorcontrib>Jiang, Shuo</creatorcontrib><creatorcontrib>Tian, Song</creatorcontrib><creatorcontrib>Xu, Tonghao</creatorcontrib><creatorcontrib>Hu, Sha</creatorcontrib><creatorcontrib>Yang, Guizhi</creatorcontrib><creatorcontrib>Zhang, Yan</creatorcontrib><creatorcontrib>Wang, Weixuan</creatorcontrib><creatorcontrib>Wang, Lexun</creatorcontrib><creatorcontrib>Zhu, Qing</creatorcontrib><creatorcontrib>Rong, Xianglu</creatorcontrib><creatorcontrib>Guo, Jiao</creatorcontrib><title>Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway</title><title>Hepatology (Baltimore, Md.)</title><addtitle>Hepatology</addtitle><description>Background and Aims
Nonalcoholic fatty liver disease, especially nonalcoholic steatohepatitis (NASH), has become a major cause of liver transplantation and liver‐associated death. NASH is the hepatic manifestation of metabolic syndrome and is characterized by hepatic steatosis, inflammation, hepatocellular injury, and different degrees of fibrosis. However, there is no US Food and Drug Administration–approved medication to treat this devastating disease. Therapeutic activators of the AMP‐activated protein kinase (AMPK) have been proposed as a potential treatment for metabolic diseases such as NASH. Cordycepin, a natural product isolated from the traditional Chinese medicine Cordyceps militaris, has recently emerged as a promising drug candidate for metabolic diseases.
Approach and Results
We evaluated the effects of cordycepin on lipid storage in hepatocytes, inflammation, and fibrosis development in mice with NASH. Cordycepin attenuated lipid accumulation, inflammation, and lipotoxicity in hepatocytes subjected to metabolic stress. In addition, cordycepin treatment significantly and dose‐dependently decreased the elevated levels of serum aminotransferases in mice with diet‐induced NASH. Furthermore, cordycepin treatment significantly reduced hepatic triglyceride accumulation, inflammatory cell infiltration, and hepatic fibrosis in mice. In vitro and in vivo mechanistic studies revealed that a key mechanism linking the protective effects of cordycepin were AMPK phosphorylation–dependent, as indicated by the finding that treatment with the AMPK inhibitor Compound C abrogated cordycepin‐induced hepatoprotection in hepatocytes and mice with NASH.
Conclusion
Cordycepin exerts significant protective effects against hepatic steatosis, inflammation, liver injury, and fibrosis in mice under metabolic stress through activation of the AMPK signaling pathway. Cordycepin might be an AMPK activator that can be used for the treatment of NASH.</description><subject>AMP-Activated Protein Kinases - metabolism</subject><subject>Animals</subject><subject>Cell Line</subject><subject>Cordycepin</subject><subject>Deoxyadenosines - pharmacology</subject><subject>Deoxyadenosines - therapeutic use</subject><subject>Fatty liver</subject><subject>Fibrosis</subject><subject>Hepatocytes</subject><subject>Hepatology</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Kinases</subject><subject>Liver</subject><subject>Liver - drug effects</subject><subject>Liver - immunology</subject><subject>Liver - pathology</subject><subject>Liver Cirrhosis - immunology</subject><subject>Liver Cirrhosis - pathology</subject><subject>Liver Cirrhosis - prevention & control</subject><subject>Liver diseases</subject><subject>Liver transplantation</subject><subject>Metabolic disorders</subject><subject>Metabolic rate</subject><subject>Metabolic syndrome</subject><subject>Mice</subject><subject>Natural products</subject><subject>Non-alcoholic Fatty Liver Disease - drug therapy</subject><subject>Non-alcoholic Fatty Liver Disease - immunology</subject><subject>Non-alcoholic Fatty Liver Disease - pathology</subject><subject>Original</subject><subject>Phosphorylation</subject><subject>Protein kinase</subject><subject>Signal transduction</subject><subject>Signal Transduction - drug effects</subject><subject>Signal Transduction - immunology</subject><subject>Steatosis</subject><subject>Traditional Chinese medicine</subject><issn>0270-9139</issn><issn>1527-3350</issn><issn>1527-3350</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><recordid>eNp1kc1uEzEURi0EomlhwQsgS2xgMa3HP2PPBimKCkUUiFRYW459J-NqMg6202p2fQSekSfBkFABEt5Y9j0699ofQs9qcloTQs962J6yWvL2AZrVgsqKMUEeohmhklRtzdojdJzSNSGk5VQ9RkelLhvCxAxNixDdZGHrRzzfwOBDNBkS_hhGM9jQh8FbfJXB5FC6mOyzT3g14bnN_qYcw4hDh3MPeP5h-f3u2-EeHF7GkKFY3_vRJMBXfl2Mflzjpcn9rZmeoEedGRI8Pewn6Mub88-Li-ry09t3i_llZTlnbWWlMorJRjpGbGONM9YJK0TTKAOsIS0zgrZy1dTQdZ0jUjmrBAFHHQiuHDtBr_fe7W61AWdhzNEMehv9xsRJB-P135XR93odbrTiQtaCFMHLgyCGrztIWW98sjAMZoSwS5py1VLBBaMFffEPeh12sby7UKLhZRHCCvVqT9kYUorQ3Q9TE_0zUF2-Wv8KtLDP_5z-nvydYAHO9sCtH2D6v0lfnC_3yh95RK3q</recordid><startdate>202108</startdate><enddate>202108</enddate><creator>Lan, Tian</creator><creator>Yu, Yang</creator><creator>Zhang, Jing</creator><creator>Li, Haonan</creator><creator>Weng, Qiqing</creator><creator>Jiang, Shuo</creator><creator>Tian, Song</creator><creator>Xu, Tonghao</creator><creator>Hu, Sha</creator><creator>Yang, Guizhi</creator><creator>Zhang, Yan</creator><creator>Wang, Weixuan</creator><creator>Wang, Lexun</creator><creator>Zhu, Qing</creator><creator>Rong, Xianglu</creator><creator>Guo, Jiao</creator><general>Wolters Kluwer Health, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5783-6883</orcidid></search><sort><creationdate>202108</creationdate><title>Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway</title><author>Lan, Tian ; Yu, Yang ; Zhang, Jing ; Li, Haonan ; Weng, Qiqing ; Jiang, Shuo ; Tian, Song ; Xu, Tonghao ; Hu, Sha ; Yang, Guizhi ; Zhang, Yan ; Wang, Weixuan ; Wang, Lexun ; Zhu, Qing ; Rong, Xianglu ; Guo, Jiao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4439-c78a83767d30c6cadacd5c55668ae36093a5297b61efffd078dc850ed2de548d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>AMP-Activated Protein Kinases - metabolism</topic><topic>Animals</topic><topic>Cell Line</topic><topic>Cordycepin</topic><topic>Deoxyadenosines - pharmacology</topic><topic>Deoxyadenosines - therapeutic use</topic><topic>Fatty liver</topic><topic>Fibrosis</topic><topic>Hepatocytes</topic><topic>Hepatology</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Kinases</topic><topic>Liver</topic><topic>Liver - drug effects</topic><topic>Liver - immunology</topic><topic>Liver - pathology</topic><topic>Liver Cirrhosis - immunology</topic><topic>Liver Cirrhosis - pathology</topic><topic>Liver Cirrhosis - prevention & control</topic><topic>Liver diseases</topic><topic>Liver transplantation</topic><topic>Metabolic disorders</topic><topic>Metabolic rate</topic><topic>Metabolic syndrome</topic><topic>Mice</topic><topic>Natural products</topic><topic>Non-alcoholic Fatty Liver Disease - drug therapy</topic><topic>Non-alcoholic Fatty Liver Disease - immunology</topic><topic>Non-alcoholic Fatty Liver Disease - pathology</topic><topic>Original</topic><topic>Phosphorylation</topic><topic>Protein kinase</topic><topic>Signal transduction</topic><topic>Signal Transduction - drug effects</topic><topic>Signal Transduction - immunology</topic><topic>Steatosis</topic><topic>Traditional Chinese medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lan, Tian</creatorcontrib><creatorcontrib>Yu, Yang</creatorcontrib><creatorcontrib>Zhang, Jing</creatorcontrib><creatorcontrib>Li, Haonan</creatorcontrib><creatorcontrib>Weng, Qiqing</creatorcontrib><creatorcontrib>Jiang, Shuo</creatorcontrib><creatorcontrib>Tian, Song</creatorcontrib><creatorcontrib>Xu, Tonghao</creatorcontrib><creatorcontrib>Hu, Sha</creatorcontrib><creatorcontrib>Yang, Guizhi</creatorcontrib><creatorcontrib>Zhang, Yan</creatorcontrib><creatorcontrib>Wang, Weixuan</creatorcontrib><creatorcontrib>Wang, Lexun</creatorcontrib><creatorcontrib>Zhu, Qing</creatorcontrib><creatorcontrib>Rong, Xianglu</creatorcontrib><creatorcontrib>Guo, Jiao</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Wiley Free Content</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Hepatology (Baltimore, Md.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lan, Tian</au><au>Yu, Yang</au><au>Zhang, Jing</au><au>Li, Haonan</au><au>Weng, Qiqing</au><au>Jiang, Shuo</au><au>Tian, Song</au><au>Xu, Tonghao</au><au>Hu, Sha</au><au>Yang, Guizhi</au><au>Zhang, Yan</au><au>Wang, Weixuan</au><au>Wang, Lexun</au><au>Zhu, Qing</au><au>Rong, Xianglu</au><au>Guo, Jiao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway</atitle><jtitle>Hepatology (Baltimore, Md.)</jtitle><addtitle>Hepatology</addtitle><date>2021-08</date><risdate>2021</risdate><volume>74</volume><issue>2</issue><spage>686</spage><epage>703</epage><pages>686-703</pages><issn>0270-9139</issn><issn>1527-3350</issn><eissn>1527-3350</eissn><abstract>Background and Aims
Nonalcoholic fatty liver disease, especially nonalcoholic steatohepatitis (NASH), has become a major cause of liver transplantation and liver‐associated death. NASH is the hepatic manifestation of metabolic syndrome and is characterized by hepatic steatosis, inflammation, hepatocellular injury, and different degrees of fibrosis. However, there is no US Food and Drug Administration–approved medication to treat this devastating disease. Therapeutic activators of the AMP‐activated protein kinase (AMPK) have been proposed as a potential treatment for metabolic diseases such as NASH. Cordycepin, a natural product isolated from the traditional Chinese medicine Cordyceps militaris, has recently emerged as a promising drug candidate for metabolic diseases.
Approach and Results
We evaluated the effects of cordycepin on lipid storage in hepatocytes, inflammation, and fibrosis development in mice with NASH. Cordycepin attenuated lipid accumulation, inflammation, and lipotoxicity in hepatocytes subjected to metabolic stress. In addition, cordycepin treatment significantly and dose‐dependently decreased the elevated levels of serum aminotransferases in mice with diet‐induced NASH. Furthermore, cordycepin treatment significantly reduced hepatic triglyceride accumulation, inflammatory cell infiltration, and hepatic fibrosis in mice. In vitro and in vivo mechanistic studies revealed that a key mechanism linking the protective effects of cordycepin were AMPK phosphorylation–dependent, as indicated by the finding that treatment with the AMPK inhibitor Compound C abrogated cordycepin‐induced hepatoprotection in hepatocytes and mice with NASH.
Conclusion
Cordycepin exerts significant protective effects against hepatic steatosis, inflammation, liver injury, and fibrosis in mice under metabolic stress through activation of the AMPK signaling pathway. Cordycepin might be an AMPK activator that can be used for the treatment of NASH.</abstract><cop>United States</cop><pub>Wolters Kluwer Health, Inc</pub><pmid>33576035</pmid><doi>10.1002/hep.31749</doi><tpages>18</tpages><orcidid>https://orcid.org/0000-0002-5783-6883</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0270-9139 |
ispartof | Hepatology (Baltimore, Md.), 2021-08, Vol.74 (2), p.686-703 |
issn | 0270-9139 1527-3350 1527-3350 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8457150 |
source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | AMP-Activated Protein Kinases - metabolism Animals Cell Line Cordycepin Deoxyadenosines - pharmacology Deoxyadenosines - therapeutic use Fatty liver Fibrosis Hepatocytes Hepatology Humans Inflammation Kinases Liver Liver - drug effects Liver - immunology Liver - pathology Liver Cirrhosis - immunology Liver Cirrhosis - pathology Liver Cirrhosis - prevention & control Liver diseases Liver transplantation Metabolic disorders Metabolic rate Metabolic syndrome Mice Natural products Non-alcoholic Fatty Liver Disease - drug therapy Non-alcoholic Fatty Liver Disease - immunology Non-alcoholic Fatty Liver Disease - pathology Original Phosphorylation Protein kinase Signal transduction Signal Transduction - drug effects Signal Transduction - immunology Steatosis Traditional Chinese medicine |
title | Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP‐Activated Protein Kinase Signaling Pathway |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T00%3A24%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cordycepin%20Ameliorates%20Nonalcoholic%20Steatohepatitis%20by%20Activation%20of%20the%20AMP%E2%80%90Activated%20Protein%20Kinase%20Signaling%20Pathway&rft.jtitle=Hepatology%20(Baltimore,%20Md.)&rft.au=Lan,%20Tian&rft.date=2021-08&rft.volume=74&rft.issue=2&rft.spage=686&rft.epage=703&rft.pages=686-703&rft.issn=0270-9139&rft.eissn=1527-3350&rft_id=info:doi/10.1002/hep.31749&rft_dat=%3Cproquest_pubme%3E2564444003%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2564444003&rft_id=info:pmid/33576035&rfr_iscdi=true |